SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug

Impressive safety and efficacy for solid cancer patients followed by global clinical study plan

Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran

Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension

Insmed announces positive results from Phase III arise study of ARIKAYCE

Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year

Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer

SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators

Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule

UTD2 is the world's first oral epothilone microtubule inhibitor

Dr. Reddy's completes Phase I study (IV route) of a proposed biosimilar of tocilizumabp

The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable

Suven Life Sciences completes enrollment of patients to the phase-2, PoC clinical study of samelisant for the treatment of narcolepsy

Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada

Merck partners with California-based research group to study catalysis innovation through machine learning

Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques